Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At ~~March 31,~~June 30, 2021 and ~~May 7,~~August 13, 2021, ~~76,377,938~~79,902,938 and ~~79,377,938~~ 80,152,938 shares of common stock were outstanding, respectively.

~~The accompanying notes are an integral part of these unaudited condensed consolidated financial statements~~

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

The accompanying notes are an integral part of these unaudited condensed consolidated financial ~~statements~~statements.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

The unaudited condensed consolidated financial statements for the three months ended ~~March 31,~~June 30, 2021 and 2020 include the accounts of American Cannabis Company, Inc. and its wholly owned subsidiary, Hollister & Blacksmith, Inc., doing business as American Cannabis Company, Inc. Intercompany accounts and transactions have been eliminated.

American Cannabis Company, Inc. and its wholly owned subsidiary Company, Hollister & Blacksmith, Inc., doing business as American Cannabis Consulting (“American Cannabis Consulting”), (collectively “the “Company”) are based in Denver, Colorado and operate a fully-integrated business model that features end-to-end solutions for businesses operating in the regulated cannabis industry in states and countries where cannabis is regulated and/or has been de-criminalized for medical use and/or legalized for recreational use. We provide advisory and consulting services specific to this industry, design industry-specific products and facilities, and sell both exclusive and non-exclusive customer products commonly used in the industry.

On April 30, 2021, the Company closed its acquisition of the assets of Medihemp, LLC, and its wholly owned subsidiary SLAM Enterprises, LLC, and Medical Cannabis Caregivers, Inc., each an entity organized and operating under the laws of the State of Colorado, and all doing business as “Naturaleaf” in the medicinal cannabis industry in Colorado.

As a result, the Company has expanded its business model to include the cultivation and retail sale of cannabis in the medicinal cannabis industry.

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include normal recurring adjustments that are necessary for a fair presentation of the results for the periods presented.

The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amount of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the condensed consolidated financial statements during the periods presented. Actual results could differ from these estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the ~~unaudited condensed~~ consolidated financial statements in the period in which they are deemed to be necessary. Significant estimates made in the accompanying consolidated financial statements include but are not limited to following those related to revenue recognition, allowance for doubtful accounts and unbilled services, lives and recoverability of equipment and other long-lived assets, the allocation of the asset purchase price, contingencies, and litigation. The Company is subject to uncertainties, such as the impact of future events, economic, environmental, and political factors, and changes in the business climate; therefore, actual results may differ from those estimates. When no estimate in a given range is deemed to be better than any other when estimating contingent liabilities, the low end of the range is accrued. Accordingly, the accounting estimates used in the preparation of the Company's ~~unaudited condensed~~ consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company's operating environment changes. Changes in estimates are made when circumstances warrant. Such changes and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the ~~unaudited condensed~~ consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting and should be read in conjunction with the consolidated financial statements and related notes of the Company and its subsidiary filed in its Annual Report on Form 10-K for the year ended December 31, 2020.S-X. Accordingly, the unaudited ~~condensed~~ consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company reports results of operations in 3 distinct segments: Consulting Services, Soil Product and Equipment and Cannabis Products.

The Consulting Services segment provides services to the Cannabis industry as to the development and expansion of cultivation and retail facilities. These services include business plans, design advice and cultivation oversight. These services are offered throughout the United States.

The Soil Product and Equipment Segment handles the sale of our So-Hum Living Soils Product and the resale of Equipment in connection with our consulting services not only in the Cannabis industry but also to other agricultural industries. These products are offered for sale throughout the United States.

The Cannabis Product segment handles both the cultivation of and the retail sale of medicinal cannabis products in the State of Colorado.

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are held in operating accounts at a major financial institution. Cash balances may exceed federally insured limits. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. As of ~~March 31,~~June 30, 2021 and December 31, 2021, the Company had cash balances in excess of FDIC insured limits of ~~$250,000.~~$250,000.

Accounts receivable are recorded at the net value of face amount less an allowance for doubtful accounts. The Company evaluates its accounts receivable periodically based on specific identification of any accounts receivable for which the Company deems the net realizable value to be less than the gross amount of accounts receivable recorded; in these cases, an allowance for doubtful accounts is established for those balances. In determining its need for an allowance for doubtful accounts, the Company considers historical experience, analysis of past due amounts, client creditworthiness and any other relevant available information. However, the Company’s actual experience may vary from its estimates. If the financial condition of its clients were to deteriorate, resulting in their inability or unwillingness to pay the Company’s fees, it may need to record additional allowances or write-offs in future periods. This risk is mitigated to the extent that the Company receives retainers from its clients prior to performing significant services.

The allowance for doubtful accounts, if any, is recorded as a reduction in revenue to the extent the provision relates to fee adjustments and other discretionary pricing adjustments. To the extent the provision relates to a client's inability to make required payments on accounts receivables, the provision is recorded in operating expenses. As of ~~March 31,~~June 30, 2021, and December 31, 2020, the Company’s allowance for doubtful accounts was ~~$60,354~~ $60,354 and ~~$57,512,~~$57,512, respectively. The Company recorded bad debt expense during the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020 of $0$0 and ~~$22,500,~~$22,500, respectively.

Deposits is comprised of advance payments made to third parties, for rent, utilities, and inventory for which the Company has not yet taken title. When the Company takes title to inventory for which deposits are made, the related amount is classified as inventory, then recognized as a cost of revenues upon sale.

During the three months ended March 31, 2021, the Company made deposit of $20,000 on the payment price as part of the Asset Purchase Agreement to acquire of Medihemp, LLC, and its wholly owned subsidiary SLAM Enterprises, LLC, and Medical Cannabis Caregivers, Inc., all doing business as “Naturaleaf.”

Inventory is comprised of products and equipment owned by the Company to be sold to end-customers. ~~Inventory~~The Company’s inventory as it relates to its soil products and equipment is valued at cost using the first-in first-out and specific identification methods, unless and until the market value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to net realizable value. As of ~~March 31,~~June 30, 2021 and December 31, ~~2020,~~2021, market values of all the Company’s inventory were greater than cost, and accordingly, no such valuation allowance was recognized.

Inventory also consists of pre-harvested cannabis plants and related end products. Inventory is valued at the lower of cost or net realizable value. Costs of inventory purchased from third party vendors for retail sales at dispensaries is determined using the first in first out method. Costs are capitalized to cultivated inventory until substantially ready for sale. Costs include direct and indirect labor, consumables, materials, packaging supplies, utilities, facilities costs, quality and testing costs, production related depreciation and other overhead costs. The Company periodically reviews physical inventory for excess, obsolete, and potentially impaired items. The reserve estimate for excess and obsolete inventory is based on expected future use and on an assessment of market conditions. At June 30, 2021, the Company’s management determined that a reserve for excess and obsolete inventory was not necessary.

Prepaid expenses and other current assets are primarily comprised of advance payments made to third parties for independent contractors’ services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods which approximate the life of the contract or service period.

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, three customers accounted for 42.5% of the Company’s total revenues for the period.

During the ~~three~~six months ended ~~March 31,~~June 30, 2020, three customers accounted for 35.4% of the Company’s total revenues.

Property and Equipment is stated at net book value, cost less depreciation. Maintenance and repairs are expensed as incurred. Depreciation of owned equipment is provided using the straight-line method over the estimated useful lives of the assets, ranging from two to seven years. Costs associated with in progress construction are capitalized as incurred and depreciation is consummated once the underlying asset is placed into service. Property and equipment are reviewed for impairment as discussed below under “Accounting for the Impairment of Long-Lived Assets.” The Company did not capitalize any interest as of ~~March 31,~~June 30, 2021 and December 31, 2020.

Goodwill represents the excess of fair value over identifiable tangible and intangible net assets acquired in business combinations. Goodwill is not amortized, instead goodwill is reviewed for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value.

The Company evaluates long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Upon such an occurrence, recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to forecasted undiscounted net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For long lived assets held for sale, assets are written down to fair value, less cost to sell. Fair value is determined based on discounted cash flows, appraised values or management's estimates, depending upon the nature of the assets. The Company had not recorded any impairment charges related to long lived assets as of ~~March 31,~~June 30, 2021 and December 31, 2020.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

Our financial instruments include cash, deposits, accounts receivable, accounts payables, advances from clients, accrued expense, and other current liabilities. The carrying values of these financial instruments approximate their fair value due to their short maturities.

We ~~recognize~~have adopted the following accounting principles related to revenue ~~in accordance~~recognition: (a) FASB ASU 2016-12 “Revenue from Contracts with ~~ASC 606 – Revenue Recognition.~~Customers (Topic 606). Due to the nature of our contracts with customers, adopting the new accounting principles did not have a significant impact on our prior period results of operations, cash flows or financial position.

Our service and product revenues arise from contracts with customers. Service revenue includes Operations Divisions consulting revenue. Product revenue includes (a) Operations Division product sales (So-Hum Living Soils) ~~and~~, (b) Equipment ~~Sales Division.~~sales division, (c) Cannabis sales division. The majority of our revenue is derived from distinct performance obligations, such as time spent delivering a service or the delivery of a specific product.

We may also enter into contracts with customers that identify a single, or few, distinct performance obligations, but that also have non-distinct, underlying performance obligations. These contracts are typically fulfilled within one to six months. Only an insignificant portion of our revenue would be assessed for allocation between distinct (contractual) performance obligations and non-distinct deliverables between reporting periods and, accordingly, we do not record a contract asset for completed, non-distinct performance obligations prior to invoicing the customer.

We recognize revenue in accordance with ASC 606 using the following 5 steps to identify revenues:

Advances from Clients deposits are contract liabilities with customers that represent our obligation to either transfer goods or services in the future, or refund the amount received. Where possible, we obtain retainers to lessen our risk of non-payment by our customers. Advances from Clients deposits are recognized as revenue as we meet specified performance obligations as detailed in the contract.

Revenue from product and equipment sales, including delivery fees, is recognized when an order has been obtained from the customer, the price is fixed and determinable when the order is placed, the product is delivered, title has transferred, and collectability is reasonably assured. Generally, our suppliers’ drop-ship orders to our clients with destination terms. The Company realizes revenue upon delivery to the customer. Given the facts that (1) our customers exercise discretion in determining the timing of when they place their product order; and, (2) the price negotiated in our product sales contracts is fixed and determinable at the time the customer places the order, we are not of the opinion that our product sales indicate or involve any significant financing that would materially change the amount of revenue recognized under the contract, or would otherwise contain a significant financing component for us or the customer under FASB ASC Topic 606. During the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020, sales returns were $0.

We also generate revenues from professional services consulting agreements. These arrangements are generally entered into: (1) on an hourly basis for a fixed fee; or (2) on a contingent fee basis. Generally, we require a complete or partial prepayment or retainer prior to performing services.

For hourly based fixed fee service contracts, we utilize and rely upon the proportional performance method, which recognizes revenue as services are completed. Under this method, in order to determine the amount of revenue to be recognized, we calculate the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. We segregate upon entry into a contract any advances or retainers received from clients for fixed fee hourly services into a separate “Advances from Clients” account, and only recognize revenues as we incur and charge billable hours, and then deposit the funds earned into our operating account. Because our hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, we are of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing, that would materially change the amount of revenue we recognize under the contract or would otherwise contain a significant financing component under FASB ASC Topic 606.

Occasionally, our fixed-fee hourly engagements are recognized under the completed performance method. Some fixed fee arrangements are for completion of a final deliverable or act which is significant to the arrangement. These engagements do not generally exceed a one-year term. If the performance is for a final deliverable or act, we recognize revenue under the completed performance method, in which revenue is recognized once the final act or deliverable is performed or delivered for a fixed fee. Revenue recognition is affected by a number of factors that change the estimated amount of work required to complete the deliverable, such as changes in scope, timing, awaiting notification of license award from local government, and the level of client involvement. Losses, if any, on fixed-fee engagements are recognized in the period in which the loss first becomes probable and reasonably estimable. FASB ASC Topic 606 provides a practical expedient to disregard the effects of a financing component if the period between payment and performance is one year or less. As our fixed fee hourly engagements do not exceed one year, no significant customer-based financing is implicated under FASB ASC Topic 606. During the three months ended March 31, 2021 and 2020, we incurred no losses from fixed fee engagements that terminate prior to completion. We believe if an engagement terminates prior to completion, we can recover the costs incurred related to the services provided.

We primarily enter into arrangements for which fixed and determinable revenues are contingent and agreed upon achieving a pre-determined deliverable or future outcome. Any contingent revenue for these arrangements is not recognized until the contingency is resolved and collectability is reasonably assured.

Our arrangements with clients may include terms to deliver multiple services or deliverables. These contracts specifically identify the services to be provided with the corresponding deliverable. The value for each deliverable is determined based on the prices charged when each element is sold separately or by other vendor-specific objective evidence (“VSOE”) or estimates of stand-alone selling prices. Revenues are recognized in accordance with our accounting policies for the elements as described above (see Product Sales). The elements qualify for separation when the deliverables have value on a stand-alone basis and the value of the separate elements can be established by VSOE or an estimated selling price.

While assigning values and identifying separate elements requires judgment, selling prices of the separate elements are generally readily identifiable as fixed and determinable as we also sell those elements individually outside of a multiple services engagement. Contracts with multiple elements typically incorporate a fixed-fee or hourly pricing structure. Arrangements are typically terminable by either party upon sufficient notice or do not include provisions for refunds relating to services provided.

Reimbursable expenses, including those relating to travel, other out-of-pocket expenses and any third-party costs, are included as a component of revenues. Typically, an equivalent amount of reimbursable expenses is included in total direct client service costs. Reimbursable expenses related to time and materials and fixed-fee engagements are recognized as revenue in the period in which the expense is incurred and collectability is reasonably assured. Taxes collected from customers and remitted to governmental authorities are recognized as liabilities and paid to the appropriate government entities.

Revenues consist of the retail sale of cannabis and related products. Revenue is recognized at the point of sale for retail customers. Payment is typically due upon transferring the goods to the customer or within a specified time period permitted under the Company’s credit policy. Sales discounts were not material during the three months ended June 30, 2021.

The Company offers a loyalty reward program to its dispensary customers that provides a discount on purchases based upon the total amount of a purchase, at the time of purchase. Management has determined that as there is no separate performance obligation to the reward program, i.e. the accumulation and redemption of points, and as such the Company recognizes the revenue at the time of purchase.

The Company’s policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenue includes the costs directly attributable to revenue recognition and includes compensation and fees for services, travel and other expenses for services and costs of products and equipment. Selling, general and administrative expenses are charged to expense as incurred.

Advertising and Promotion costs are included as a component of selling and marketing expense and are expensed as incurred. During the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020 these expenses were ~~$11,888~~$33,238 and ~~$6,000,~~$8,489, respectively.

For product and equipment sales, shipping and handling costs are included as a component of cost of revenues.

Restricted shares are awarded to employees and entitle the grantee to receive shares of common stock at the end of the established vesting period. The fair value of the grant is based on the stock price on the date of grant. We recognize related compensation costs on a straight-line basis over the requisite vesting period of the award, which to date has been one year from the grant date. During the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020, stock-based compensation expense for restricted shares for Company employees was ~~$15,664~~$28,690 and ~~$4,503, respectively.~~$4,503, respectively and $13,027 and $19,659 for the three months ended June 30, 2021. Compensation expense for warrants are based on the fair value of the instruments on the grant date, which is determined using the Black-Scholes valuation model and are expensed over the expected term of the awards.

During the six months ended June 30, 2021, no warrants were issued as stock compensation.

As a component of our equipment and supplies offerings, from time-to-time we design and develop our own proprietary products to meet demand in markets where current offerings are insufficient. These products include, but are not limited to: The Satchel™, Cultivation Cube™, So-Hum Living Soils™ and the HDCS™. Costs associated with the development of new products are expensed as incurred as research and development operating expenses. During the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020, our research and development costs were de minimis.

The Company’s corporate status changed from an S Corporation, which it had been since inception, to a C Corporation during the year ended December 31, 2014. As provided in Section 1361 of the Internal Revenue Code, for income tax purposes, S Corporations are not subject to corporate income taxes; instead, the owners are taxed on their proportionate share of the S Corporation’s taxable income. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the ~~unaudited condensed~~ consolidated financial statements or tax returns in accordance with applicable accounting guidance for accounting for income taxes, using currently enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. For the year ended December 31, 2010, due to cumulative losses since our corporate status changed, we recorded a valuation allowance against our deferred tax asset that reduced our income tax benefit for the period to zero. As of ~~March 31,~~June 30, 2021 and December 31, 2020, we had no liabilities related to federal or state income taxes and the carrying value of our deferred tax asset was zero.

The Company reports net loss per common share in accordance with FASB ASC 260, “Earnings per Share”. This statement requires dual presentation of basic and diluted earnings with a reconciliation of the numerator and denominator of the earnings per share computations. Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share is equal to basic earnings per share because there are no potential dilatable instruments that would have an anti-dilutive effect on earnings. Diluted net loss per share gives effect to any dilutive potential common stock outstanding during the period. The computation does not assume conversion, exercise or contingent exercise of securities since that would have an anti-dilutive effect on earnings.

Due to its cannabis operations, the Company is subject to the limitations of Internal Revenue Code (“IRC”) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.

The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

On March 11, 2020, the World Health Organization declared the current coronavirus (“COVID-19”) outbreak to be a global pandemic. In response to this declaration and the rapid spread of COVID-19 within the United States, federal, state and local governments throughout the country have imposed varying degrees of restrictions on social and commercial activity to promote social distancing in an effort to slow the spread of the illness. These measures had a significant adverse impact upon many sectors of the economy, including retail commerce.

In response to state and local measures and for protection of both employees, the Company made required changes to operations, which did not have a material impact upon operations or the financial condition of the Company.

While the state and local governments have eased restrictions on restrictions and activities, it is possible that a resurgence in COVID-19 cases could prompt a return to or new tighter restrictions to be instituted in the future. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of these unaudited condensed consolidated financial statements.

Recent accounting pronouncements that the Company has adopted or that will be required to adopt in the future are summarized below.

In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes”. The pronouncement simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, “Income Taxes”. The pronouncement also improves consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is still evaluating the impact this guidance will have on its ~~unaudited condensed~~ consolidated financial statements.

In January 2020, the FASB issued ASU No. 2020-01, "Investments — Equity Securities: Clarifying the Interactions between Topic 321, Topic 323, and Topic 815" ("ASU No. 2020-01"). ASU No. 2020-01 clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with ASC 321, "Investments — Equity Securities" immediately before applying or upon discontinuing the equity method of accounting in ASC 323, "Investments—Equity Method and Joint Ventures." The provisions of ASU No. 2020-01 are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years with early adoption permitted, including early adoption in an interim period for public business entities for periods for which financial statements have not yet been issued. The Company is still evaluating the impact this guidance will have on its consolidated financial statements.

One Marijuana Infused Product Licenses (MIPS); and,

One Option Premises Cultivation License (OPC); and,

Related real property assets, goodwill, and related business assets.

The aggregate consideration paid for the Assets was $2,890,000, which consisted of (i) a cash payment of $1,100,000, (ii) the issuance of a promissory note to the owner of Naturaleaf in the principal amount of $1,100,000 (the “Seller Note”), and (iii) the issuance of 3,000,000 shares of the Company’s restricted common stock valued at $0.23 per share or $690,000.

The asset acquisition was accounted for under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. As the acquirer for accounting purposes, the Company has estimated the fair value of Medihemp LLC and Medical Cannabis Caregivers, Inc.’s (hereafter “Naturaleaf’s”) assets acquired and conformed the accounting policies of Naturaleaf to its own accounting policies. The Company expensed certain legal, auditing and licensing costs with the acquisition of $83,095.

As part of the acquisition, the owners of Naturaleaf retained the outstanding cash balance on the date of the acquisition and had agreed to the payment of all outstanding accounts payables and related party advances.

The Company has performed a preliminary valuation analysis of the fair market value of Naturaleaf’s assets. The following table summarizes the allocation of the preliminary purchase price as of the acquisition date:

Purchase price as of the acquisition
Cash	$	--
Inventory		150,000
Property, plant and equipment		92,523
Long Term Deposits		6,000
Identifiable intangible assets		1,111,161
Goodwill		1,530,316
Accounts payable		--
Total consideration	$	2,890,000

Preliminary goodwill from the acquisition primarily relates to the future economic benefits arising from the assets acquired and is consistent with the Company's stated intentions and strategy. Other assets include inventory and fixed assets.

The preliminary fair value of Naturaleaf’s identifiable intangible assets was $1,111,161 million at April 30, 2021, consisting of $694,476 in licenses and $416,875 in brand names. Due to the indefinite life of the identifiable intangible assets at this time, the Company did not recognize an amortization expense during the six months ended June 30, 2021.

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(UNAUDITED)

The estimated fair values assigned to identifiable assets acquired assumed are provisional and are based on the information that was available as of the acquisition date to estimate the fair value of assets acquired and liabilities assumed. The Company believes that information provides a reasonable basis for estimating the fair values of assets acquired and liabilities assumed, but the Company is waiting for additional information necessary to finalize those fair values. Therefore, the provisional measurements of fair value reflected are subject to change and such changes could be significant. The Company expects to finalize the valuation and complete the purchase price allocation as soon as practicable, but no later than one year from the acquisition date.

The results of operations of Naturaleaf for the period from April 30, 2021 through June 30, 2021 are included in the Company's unaudited condensed consolidated financial statements as of June 30, 2021.

Unaudited Pro Forma Financial Information

The following unaudited pro forma information presents a summary of the Company’s combined operating results for the three and six months ended June 30, 2021 and 2020, as if the acquisition had occurred on January 1, 2020. The following pro forma financial information is not necessarily indicative of the Company’s operating results as they would have been had the acquisition been effected on the assumed date, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, basic shares outstanding and dilutive equivalents, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.

Pro Forma Financial Information
	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020

Total Revenues	$	808,243		$	1,162,406		$	1,712,496		$	2,468,724
Loss from Operations	$	(351,728	)	$	(8,908	)	$	(383,864	)	$	(88,189	)

Basic and diluted loss per share	$	—		$	—		$	—		$	—

Note 4. 5. Accounts Receivable and Advance from Clients

Accounts receivable was comprised of the following:

Accounts Receivable and Advance from Clients
	March 31, 2021			December 31, 2020			June 30, 2021			December 31, 2020
Accounts Receivable – Trade	$	87,622		$	82,467		$	168,101		$	82,467
Less: Allowance for Doubtful Accounts		(60,354	)		(57,512	)		(144,770	)		(57,512	)
Accounts Receivable, net	$	27,268		$	24,955		$	23,331		$	24,955

The Company had bad debt expense during the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020 ~~and 2021~~ of $0, ~~and $22,500,~~ respectively.

Our Advances from Clients had the following activity:

	Amount			Amount
December 31, 2020	$	88,843		$	88,843
Additional deposits received		126,131			199,892
Less: Deposits recognized as revenue		(151,750	)		(225,288	)
March 31, 2021	$	63,224
June 30, 2021				$	63,447

Note 5. 6. Inventory

Inventory consisted of the following:

Inventory
	March 31, 2021		December 31, 2020		June 30, 2021		December 31, 2020
Raw Materials	$	81,821	$	39,746	$	92,132	$	39,746
Work In Process						66,287		-
Finished Goods		39,633		22,656		173,075		22,656
Total Inventory	$	121,454	$	62,402	$	331,494	$	62,402

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(UNAUDITED)

Note 6. 7. Property and Equipment, net

Property and equipment, net, was comprised of the following:

Property and Equipment, Net
	March 31, 2021			December 31, 2020			June 30, 2021			December 31, 2020
Office equipment	$	35,647		$	34,072		$	38,481		$	34,071
Software		13,204			13,204			13,204			13,204
Furniture and Fixtures								2,328			-
Machinery and Equipment								329,992			-
Leasehold Improvements								115,808			-
Property and equipment, gross	$	48,851		$	47,276		$	499,813		$	47,275
Less: Accumulated Depreciation		(25,869	)		(22,621	)		(31,597	)		(22,621	)
Property and equipment, net	$	22,983		$	24,655		$	468,216		$	24,654

As part of the Naturaleaf Asset Acquistion, the Company acquired $92,535 in fixed assets consisting of machinery and equipment and leasehold improvements. During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the Company purchased office equipment in the amount of ~~$1,576.~~$1,576 and has made purchases of machinery and equipment of $308,438 in order to upgrade operations at the new cultivation facilities and has spent $50,000 in leasehold improvements at the cultivation facilities.

Note 7. 8. Accrued and Other Current Liabilities

Accrued and other current liabilities consisted of the following:

Accrued and Other Current Liabilities
	March 31, 2021		December 31, 2020		June 30, 2021		December 31, 2020
Accrued Interest	$	—	$	449	$	18,629	$	449
Accrued Payroll		12,152		—		33,112		-
Sales Tax Payable						17,633		-
Other Accrued Expenses & Payables		34,381		48,795		66,994		48,795
Accrued and other current liabilities	$	46,533	$	49,244	$	136,368	$	49,244

Note 8. 9. Stock Payable

The following summarizes the changes in common stock payable:

Schedule of stock payable
	Amount		Amount
December 31, 2020	$	—	$	-
Additional Expenses Incurred		15,664		28,690
Payments Upon Issuance of Shares		—		-
March 31, 2021	$	15,664
June 30, 2021			$	28,690

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(UNAUDITED)

Note 9. 10. Operating Lease Right-of-Use Asset/Operating Lease Liability

The Company leases property under operating leases. Property leases include retail and cultivation space with fixed rent payments and lease terms ranging from one to two years. The Company is obligated to pay the lessor for maintenance, real estate taxes, insurance and other operating expenses on certain property leases. These expenses are variable and are not included in the measurement of the lease asset or lease liability. These expenses are recognized as variable rent expense when incurred.

The Company’s lease portfolio consists of the following.

Schedule of lease
Lease Name	Asset Type	Start Date	Expiration Date	Monthly Rent
Durango Lease	Real Property	5/1/2021	5/31/2022	$	10,200
Lehman Lease	Real Property	5/1/2021	12/31/2022	$	2,732
Palmer Lease	Real Property	5/1/2021	6/30/2022	$	1,069
Greenspace Membership	Real Property	4/15/2021	12/31/2021	$	1,000
Tejon Lease	Real Property	5/1/2021	4/30/2022	$	3,700

On June 1, 2020, the Company entered into a new lease membership agreement for a one-year term for an amount of $2,895 per month, the lease expired on May 31, 2021. At that time the Company entered into an 8 ½ month lease for less space for an amount of $1,000 per month. We determined under ASC 842, due to the ~~short term~~short-term nature of the lease that the lease membership agreement met the criteria of ASC 842-20-25-2 and as such it iswas not necessary to capitalize the lease and rent will be recognized on a monthly straight-line basis.

On May 1, 2020, as part of the Naturaleaf Acquisition, leases for grow facilities and dispensaries were assigned to the Company. These leases were determined to be operating leases under ASC 842 and such leases was capitalized. It was determined that the Tejon lease, due to the short-term nature of the lease met the criteria of ASC 842-20-25-2 and as such it was not necessary to capitalize the lease and rent would be recognized on a straight-line basis.

The Company records the lease asset and lease liability at the present value of lease payments over the lease term. The leases typically do not provide an implicit rate; therefore, the Company uses its estimated incremental borrowing rate at the time of lease commencement to discount the present value of lease payments. The Company’s discount rate for operating leases at June 30, 2021 was 12.5%. Leases often include rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when appropriate. Lease expense is recognized on a straight-line basis over the lease term to the extent that collection is considered probable. As a result, the Company been recognizing rents as they become payable.

As of June 30, 2021, the maturities of operating leases liabilities are as follows:

Operating leases liabilities
	Operating Leases
2021	$	84,474
2022		91,158
Total		175,632
Less: amount representing interest		(12,216	)
Present value of future minimum lease payments		163,416
Less: current obligations under leases		147,131
Long-term lease obligations	$	16,286

As of June 30, 2021, the aggregate remaining minimal annual lease payments under these operating leases, including those accounted for under practicable expedient were as follows:

2021	$	112,213
2022		103,844
Total	$	216,057

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(UNAUDITED)

Note ~~10. Loan~~11. Loans Payable

PPP Loans

On March 27, 2020, the CARES Act was enacted to provide financial aid to family and businesses impacted by the COVID-19 pandemic. The Company participated in the CARES Act, and on August 6, 2020, the Company entered into a note payable with a bank under the Small Business Administration (“SBA”) Paycheck Protection Program (“PPP loan”) in the amount of $109,914. This loan payable matures on August 6, 2022 with a fixed interest rate of 1% per annum with interest deferred for six months. The PPP loan has an initial term of two years, is unsecured and guaranteed by the SBA. Under the terms of the PPP loan, the Company may apply for forgiveness of the amount due on the PPP loan. The Company used the proceeds from the PPP loan for qualifying expenses as defined in the PPP. The Company intends to apply for forgiveness of the PPP loan in accordance with the terms of the CARES Act. However, the Company cannot assure at this time that the PPP loan will be forgiven partially or in full. If the loan is not forgiven based on the PPP guidelines to be issued by the SBA, as defined, then, the monthly payment amount will be $6,186 beginning on March 6, 2021 through August 6, 2022. On March 3, 2021, the SBA forgave the principal of $109,914 and any accrued interest at that time.

On April 23, 2021, the Company entered into a second note payable with a bank under the SBA PPP Loan in the amount of $130,186. The PPP Loan is subject to the same terms of forgiveness as above. The monthly payment amount will be $3,056 beginning on September 22, 2022.

Naturaleaf Seller Note

As part of the Naturaleaf Acquisition, the Company issued a promissory note to the owner of Naturaleaf in the principal amount of $1,100,000 (the “Seller Note”). The note has a term of 1 year with a due date of April 1, 2022 and does not require any payments prior to the due date. The note has an annual interest rate of 10%. At June 30, 2021, interest of $18,383 had been accrued.

Note ~~11.~~ 12. Related Party Transactions

The Company has a related party entity, Tabular Investments, LLC (“Tabular”) which was set to assign the Company’s interest in various equity partnership. The sole member of Tabular is Tad Mailander, the Company’s outside legal counsel and Director. The Company has valued all of its equity partnership investments at $0. Neither our direct equity ownership in, nor our assignments of equity to Tabular Investments, LLC are, or are reasonably likely to allow for, substantive terms, transactions, and arrangements, whether contractual or not contractual, that will have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We have no direct or indirect majority influence or control over any entity in which we have a direct equity interest or equity interests assigned to Tabular. We do not have any direct or indirect interest in, and do not control Tabular. We have not absorbed losses from either our direct equity interests or assignments to Tabular, and we have provided no subordinated financial support to any project

Note ~~12.~~ 13. Stock Based Compensation

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the Company issued stock-based compensation for employees and service providers pursuant to its 2015 Equity Incentive Plan. ~~During the years ended December 31, 2020, the Company’s expense for restricted shares to Company employees was $15,664 and $4,503 which was the result of the following activity:~~

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(UNAUDITED)

Restricted Shares

From time to time, the Company grants certain employees restricted shares of its common stock to provide further compensation in-lieu of wages and to align the employee’s interests with the interests of its stockholders. Because vesting is based on continued employment, these equity-based incentives are also intended to attract, retain and motivate personnel upon whose judgment, initiative and effort the Company’s success is largely dependent.

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the Company granted ~~67,808~~ 135,616 restricted shares and recognized ~~$15,664~~$28,690 in associated employee stock-based compensation expense , which ~~have not been issued at March 31, 2021. The shares are not issued until terms set by~~is included as part of the ~~Board of Directors are met and so the shares earned are treated as a~~outstanding stock payable ~~until such time that they are issued.~~June 30, 2021. The fair value of restricted stock unit is determined based on the quoted closing price of the Company’s common stock on the date grant.

During the ~~three~~six months ended ~~March 31,~~June 30, 2020, the Company granted ~~89,708~~ 225,000 restricted shares and recognized ~~$4,503~~$19,347 in associated employee stock-based compensation ~~expense.~~expense, which is included as part of the outstanding stock payable June 30, 2020, that was issued in December 2020. The fair value of the restricted stock is determined based on the quoted closing price of the Company’s common stock on the date of grant.

During the ~~three~~six months ended ~~March 31,~~June 30, 2020, the Company issued 478,261 shares of restricted shares granted during the fiscal year ended December 31, 2019.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the reporting period. Diluted net loss per share is computed similarly to basic loss per share, except that it includes the potential dilution that could occur if dilutive securities are exercised.

Outstanding stock options and common stock warrants are considered anti-dilutive because we are in a net loss position. Accordingly, the number of weighted average shares outstanding for basic and fully diluted net loss per share are the same.

The following summarizes equity instruments that may, in the future, have a dilutive effect on earnings per share:

Schedule of stock based compensation
	March 31, 2021		December 31, 2020		June 30, 2021		December 31, 2020
Warrants		10,000		397,500		10,000		397,500
Stock Payables		67,808		—
Stock Payable						135,616		-
Total		77,808		397,500		145,616		397,500

Warrants

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, warrants with a cashless exercise provision were exercised for ~~100,000~~125,000 restricted shares . Of which, a warrant for 100,000 shares was exercised by an officer/director of the Company.

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the Company did not issue or approve any warrants. Warrants exercisable for 287,500 shares expired.

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(UNAUDITED)

Note ~~13.~~ 14. Shareholders’ Equity

Preferred Stock

American Cannabis Company, Inc. is authorized to issue 5,000,000 shares of preferred stock at $0.01 par value. No shares of preferred stock were issued and outstanding at ~~March 31,~~June 30, 2021 and December 31, 2020, respectively.

Common Stock

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the Company issued 3,000,000 shares of its restricted common stock to the sellers of Naturaleaf, as part of the acquisition of assets of Naturaleaf. The shares had a value of $690,000 based on a closing market price on April 23, 2021 of $0.23 per share.

During the six months ended June 30, 2021, warrants with a cashless exercise provision were exercised for ~~100,000~~125,000 restricted shares . Of which, a warrant for 100,000 shares was exercised by an officer/director of the Company.

During the ~~three~~six months ended ~~March 31,~~June 30, 2020, the Company issued 478,261 shares of restricted shares granted during the fiscal year ended December 31, 2019.

Note ~~14.~~ 15. Commitments and Contingencies

Legal

In the ordinary course of its business, the Company becomes involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material adverse effect on the Company’s business, consolidated financial position, results of operations, or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Companies expenses legal fees in the period in which they are incurred.

Turoff Matter

On November 15, 2019, Erin Turoff filed suit against the Company and Mr. Terry Buffalo, our chief executive officer and director, and Mr. Ellis Smith our chief development officer and director, in Denver County District Court. The complaint seeks a declaratory judgement and damages related to Ms. Turoff’s allegation that she was misclassified as an independent contractor while working for the Company. ~~The action~~Ms. Turoff alleges she is owed unpaid overtime, liquidated damages, wages, and other compensatory damages for her misclassification and alleged wrongful terminations. Ms. Turoff’s suit against Mr. Buffalo and Mr. Smith alleges that each are the alter ego of the Company and are therefore jointly and severally liable. All parties have appeared in ~~preliminary stage,~~the case and the case is currently in the discovery. At this time, there is no reasonable basis from which a determination or estimate may be made concerning any contingent liability related to ~~determine or reasonably calculate a contingent legal liability expense as of the date of~~ this ~~filing.~~lawsuit.

AMERICAN CANNABIS COMPANY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(UNAUDITED)

Note ~~15.~~ 16. Subsequent Events

~~Naturaleaf Acquisition~~

On April 30, 2021, the Company closed its acquisition of Medihemp, LLC, and its wholly owned subsidiary SLAM Enterprises, LLC, and Medical Cannabis Caregivers, Inc., each an entity organized and operating under the laws of the State of Colorado, and all doing business as “Naturaleaf.”

Previously, on March 11, 2021, the Company signed an Asset Purchase Agreement to acquire the entities. In exchange for a deposit of $20,000, a subsequent payment $1,080,000 dollars, the execution of a promissory note for $1.1 million dollars, and the issuance of three million shares of common stock Naturaleaf agreed to sell the Company the following assets:

~~Three Medical Marijuana (MMC) Store Licenses;~~

~~One Marijuana Infused Product Licenses (MIPS); and,~~

~~One Option Premises Cultivation License (OPC); and,~~

~~Related real property assets, good will, and related business assets.~~

A condition precedent to closing the transaction was obtaining the approval of the Colorado MED and City of Colorado Springs to the change of ownership over the cannabis licenses. In the event MED and City do not approve the license transfers, the asset purchase agreement will terminate, and the Company will forfeit its initial $20,000 payment. On April 30, 2021, Colorado MED and the City of Colorado Springs granted approval and the transaction closed. The Company paid $1,080,000 in cash, executed a promissory note for $1.1 million dollars and issued three million shares of restricted common stock to Naturaleaf.

~~PPP Loan~~

On March 27, 2020, the CARES Act was enacted to provide financial aid to family and businesses impacted by the COVID-19 pandemic. In late 2020, a second round of funding was authorized and made available. The Company on April 22, 2021, the Company entered into a note payable with a bank under the Small Business Administration (“SBA”) Paycheck Protection Program (“PPP loan”) in the amount of $130,186. This loan payable matures on April 26, 2026 with a fixed interest rate of 1% per annum with interest deferred for six months. The PPP loan has an initial term of two years, is unsecured and guaranteed by the SBA. Under the terms of the PPP loan, the Company may apply for forgiveness of the amount due on the PPP loan. The Company used the proceeds from the PPP loan for qualifying expenses as defined in the PPP. The Company intends to apply for forgiveness of the PPP loan in accordance with the terms of the CARES Act. However, the Company cannot assure at this time that the PPP loan will be forgiven partially or in full. If the loan is not forgiven based on the PPP guidelines to be issued by the SBA, as defined.

In accordance with ASC 855-10, the Company has analyzed its operations after ~~December 31, 2020 to the date these~~ Unaudited ~~condensed~~ consolidated financial statements were available to be issued and has determined that there were no other significant subsequent events or transactions that would require recognition or disclosure in the unaudited condensed consolidated financial statements for the ~~three~~six months ended ~~March 31, 2021.~~June 30, 2021, other than as follows.

In August 2021, the Company issued 250,000 registered shares of common stock in exchange for net proceeds of $26,935 pursuant to the Common Stock Purchase Agreement entered into on October 11, 2019 with White Lion Capital LLC.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The statements contained in this report that are not statements of historical fact, including without limitation, statements containing the words “believes,” “expects,” “anticipates” and similar words, constitute forward looking statements that are subject to a number of risks and uncertainties. From time to time we may make other forward-looking statements. Investors are cautioned that such forward looking statements are subject to an inherent risk that actual results may materially differ as a result of many factors, including the risks discussed from time to time in this report, including the risks described under “Risk Factors” in any filings we have made with the SEC.

Government Regulation

Currently, there are thirty-six states plus the District of Columbia that have laws and/or regulation that recognize in one form or another legitimate medical uses for cannabis and consumer use of cannabis in connection with medical treatment. There are currently sixteen states and the District of Columbia that allow recreational use of cannabis. As of June 30, 2021, the policy and regulations of the Federal Government and its agencies is that cannabis has no medical benefit and a range of activities including cultivation and use of cannabis for personal use is prohibited on the basis of federal law and may or may not be permitted on the basis of state law. Active enforcement of the current federal regulatory position on cannabis on a regional or national basis may directly and adversely affect the willingness of customers of the Company’s medicinal cannabis products to invest in or buy products. Active enforcement of the current federal regulatory position on cannabis may thus indirectly and adversely affect revenues and profits of the Company.

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates, including those related to useful lives of real estate assets, bad debts, impairment, net lease intangibles, contingencies, and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates.

BACKGROUND

American Cannabis Company, Inc. and subsidiary company, Hollister & Blacksmith, Inc., doing business as American Cannabis Consulting (“American Cannabis Consulting”), (collectively “the “Company”, “we”, “us”, or “our”) are based in Denver, Colorado and operate a fully integrated business model that features end to end solutions for businesses operating in the regulated cannabis industry in states and countries where cannabis is regulated and/or has been decriminalized for medical use and/or legalized for recreational use. The Company provides advisory and consulting services specific to this industry, manufactures proprietary industry solutions including; the Satchel™, SoHum Living Soils™, Cultivation Cube™ and the High Density Cultivation System.™ The Company also sells 3rd party industry specific products and manages a strategic group partnership that offers both exclusive and nonexclusive customer products commonly used in the industry. American Cannabis Company, Inc. is a publicly listed company quoted on the OTCQB Tier under the symbol “AMMJ”.

Naturaleaf Acquisition

On ~~March 11,~~April 30, 2021, the Company ~~entered into an asset purchase agreement with~~closed its acquisition of the assets of Medihemp, LLC, ~~(“Medihemp”)~~ and its wholly owned subsidiary SLAM Enterprises, LLC, ~~(“SLAM”),~~ and Medical Cannabis Caregivers, Inc. ~~(“Medical Cannabis”)~~, each an entity organized and operating under the laws of the State of Colorado, and all doing business as ~~“Naturaleaf.”~~“Naturaleaf” in the medicinal cannabis industry in Colorado.

Medihemp and SLAM, respectively own fixed assets and operate two retail Medical Marijuana Centers located in Colorado Springs, Colorado. Medical Cannabis owns fixed assets and operates a retail Medical Marijuana Center located in Colorado Springs, Colorado. Medical Cannabis also owns and operates a Medical Marijuana Optional Premises Cultivation license, and a Medical Marijuana-Infused Product Manufacturer license.

~~As part of the Asset Purchase Agreement the Company has agreed to purchase, and Medihemp, SLAM, and Medical Cannabis~~

Naturaleaf agreed to sell ~~and/~~or assign to the Company ~~all of their respective fixed assets and associated intellectual property, including assignment of~~ the following ~~licenses issued by the Colorado Marijuana Enforcement Division (“MED”) and the corresponding City of Colorado Springs (“City”):~~assets:

o1.

~~Medihemp’s, SLAM’s and Medical Cannabis’ respective~~Three Medical Marijuana ~~Center licenses;~~(MMC) Store Licenses;

One Marijuana Infused Product Licenses (MIPS); and,

One Option Premises Cultivation License (OPC); and,

Related real property assets, goodwill, and related business assets.

~~Medical Cannabis’ Medical Marijuana Infused Product Manufacturer license; and,~~

As a result, the Company has expanded its business model to include the cultivation and retail sale of cannabis in the medicinal cannabis industry.

~~Medical Cannabis’ Medical Marijuana Optional Premises Cultivation license.~~

The ~~Company will be assuming leases for Medihemp, SLAM, and Medical Cannabis’ respective retail Medical Marijuana Centers.~~

~~The purchase price~~aggregate consideration paid for the ~~acquisition is $2.2 million dollars and~~Assets was $2,890,000, which consisted of (i) a cash payment of $1,100,000, (ii) the issuance of ~~3 million~~a promissory note to the owner of Naturaleaf in the principal amount of $1,100,000 (the “Seller Note”), and (iii) the issuance of 3,000,000 shares of the Company’s restricted common ~~stock. Payment terms required a $20,000 non-refundable payment upon signing, a cash payment~~stock valued at $0.23 per share or $690,000.

The asset acquisition was accounted for under the acquisition method of ~~$1,080,000 after~~accounting in accordance with ASC Topic 805, Business Combinations. As the ~~receipt~~acquirer for accounting purposes, the Company has estimated the fair value of Medihemp LLC and Medical Cannabis Caregivers, Inc.’s (hereafter “Naturaleaf’s”) assets acquired and conformed the accounting policies of Naturaleaf to its own accounting policies.

As part of the ~~Contingent Approval Letters~~acquisition, the owners of Naturaleaf retained the ~~Change of Ownership applications from~~outstanding cash balance on the ~~MED and City, and the balance of $1,100,000 paid pursuant to a promissory note executed by Registrant effective upon receipt of the Contingent Approval Letters. The maturity~~ date of the ~~Promissory Note is 365 days~~acquisition and had agreed to the payment of all outstanding accounts payables and related party advances.

Cash	$	--
Inventory		150,000
Property, plant and equipment		92,523
Long Term Deposits		6,000
Identifiable intangible assets		1,111,161
Goodwill		1,530,316
Accounts payable		--
Total consideration	$	2,890,000

Preliminary goodwill from the ~~Closing Date, includes 10% simple interest accruing annually,~~acquisition primarily relates to the future economic benefits arising from the assets acquired and is ~~not subject to a pre-payment penalty.~~consistent with the Company's stated intentions and strategy. Other assets include inventory and fixed assets.

The ~~closing~~preliminary fair value of the transaction is contingent upon the Registrant completing due diligence, including obtaining the audited financial statements of Medihemp, SLAM and Medical Cannabis, and the receipt of the Contingent Approval Letters from MED and City approving the transfer of the licenses to the Registrant. In the event MED and City do not approve the license transfers, the asset purchase agreement will terminate, and the Company will forfeit its initial $20,000 payment. OnNaturaleaf’s identifiable intangible assets was $1,111,161 million at April 30, 2021, ~~Colorado MED~~consisting of $$694,476 in licenses and $416,875 in brand names.

The estimated fair values assigned to identifiable assets acquired assumed are provisional and are based on the ~~City~~information that was available as of ~~Colorado Springs granted approval~~the acquisition date to estimate the fair value of assets acquired and ~~the transaction closed.~~liabilities assumed. The Company ~~paid $1,080,000 in cash, executed~~believes that information provides a ~~promissory note~~reasonable basis for ~~$1.1 million dollars~~estimating the fair values of assets acquired and ~~issued three million shares~~liabilities assumed, but the Company is waiting for additional information necessary to finalize those fair values. Therefore, the provisional measurements of ~~restricted common stock~~fair value reflected are subject to ~~Naturaleaf.~~change and such changes could be significant. The Company expects to finalize the valuation and complete the purchase price allocation as soon as practicable, but no later than one year from the acquisition date.

RESULTS OF OPERATIONS

Revenues

Total revenues were ~~$325,980~~$945,958 for the six months ended June 30, 2021 as compared to $990,295 for the six months ended June 30, 2020. Total revenues were $619,978 for the three months ended ~~March 31,~~June 30, 2021 as compared to ~~$440,382~~$549,913 for the three months ended ~~March 31, 2020.~~

Consulting service revenues during the three months ended March 31, 2021 were $161,893 versus $224,375 for the three months ended March 31, 2020. Our product and equipment revenues for the three months ended March 31, 2021 were $164,087 revenues versus $216,007 for the three months ended March 31, 2020.

June 30, 2021. The decreases in total revenue of ~~$114,402,~~$44,337, represents a decrease of ~~$62,482~~$154,221 in consulting revenue combined with a ~~$51,920~~$197,193 decrease in product and equipment ~~revenue. Decreases in consulting services is a direct result~~revenue offset by the revenue stream from the sale of ~~the effects of COVID-19 on clients plans, management has started to see a pick up in services as a result of several states legalizing~~ cannabis for medicinal and/or recreational use. Soil sales saw decrease in part due to the timing of sales requiring prepayment at the end of the quarter not being able to be shipped and therefor recognized prior to the end of the period.products.

Costs of Revenues

Costs of revenues primarily consists of labor, travel, cost of equipment and soil sold, and other costs directly attributable to providing services or soil products. Costs of revenues related to our cannabis products include cultivation costs, including labor, utilities, supplies and cultivation facility rent. During the ~~three~~six months ended ~~March 31,~~June 30, 2021, our total costs of revenues were ~~$141,809~~$503,037 compared to ~~$228,367~~$538,168 for the ~~three~~six months ended ~~March 31,~~June 30, 2020. Decreases in costs of consulting services and products and equipment were offset by $146,074 in costs associated with the Company’s cannabis products.

Consulting Services

Consulting service revenues during the six months ended June 30, 2021 were $201,393 versus $335,613 for the six months ended June 30, 2020. Decreases in consulting services is a direct result of the effects of COVID-19 on clients plans. Management had started to see an op tick in services as a result of several states legalizing cannabis for medicinal and/or recreational use in late 2020, but during the last six months the use of such services has been effected by delays in finalization of rules for implementation in those states that in 2020 legalized cannabis for either medicinal or recreational purposes.

Costs of Services were $26,706 compared to $114,555 for the six months ended June 30, 2021 and 2020. Costs associated with consulting services decreased $87,849 as the Company has focused on the use of internal staff, rather than consultants for a majority of this work.

Soil Product and Equipment Revenues

Our product and equipment revenues for the six months ended June 30, 2021 were $437,489 revenues versus $634,682 for the six months ended June 30, 2020. As a result of changes in warehousing and production practices, soil sales are seeing a decrease in the sales recognized during the period due to the timing of sales requiring prepayment at the end of the quarter not being ready for shipment in the last days of the quarter and therefor not recognizable as revenue at the prior to the end of the period.

Costs of Products and Equipment were $330,257 and $423,609, during the six months ended June 30, 2021 and 2020. Costs associated with products and equipment decreased ~~$86,558~~$93,352, from as a result of the change in the products being offered offset by an increase in cost per bag for one product.

Cannabis Product Revenues

Cannabis product revenues during the six and three months ended June 30, 2020 were $307,077, respectively. The Company acquired the assets of Naturaleaf on April 30, 2021 and only began recognizing revenues from these operations on May 1, 2021.

Costs associated with cannabis products consists of those costs incurred in the cultivation of the plants and the retail sale of the products. During the six months ended June 30, 2021 such costs were $146,074.

Gross Profit

Total gross profit was ~~$184,171~~$442,921 for the ~~three~~six months ended ~~March 31,~~June 30, 2021, compromised of consulting services gross profit of ~~$140,293 and~~$174,687, products and equipment gross profit of ~~$43,878.~~$107,232 and a gross profit of $161,003 for cannabis products. This compares to total gross profit of ~~$212,015~~$452,131 for the ~~three~~six months ended ~~March 31,~~June 30, 2020, compromised of consulting services gross profit of ~~$132,249~~$241,058 and products and equipment gross profit of ~~$79.766.~~$211,073. The relative decreases are a result of the actions described above.

The decrease in our consulting services gross profits reflects the effects of COVID-19 onwhich has been compounded by delays in finalization of rules for implementation in states that ~~delayed enacting legislation during the period to legalizing~~in 2020 legalized cannabis ~~due to issues encountered in gathering necessary signatures as quarantine and stay at home orders were going into effect and were unable to get measures on the ballots~~ for ~~the fall of 2020, and so there has been a corresponding decrease in the demand for our consulting services due to this hinderance to growth of the market.~~either medicinal or recreational purposes The decrease in gross profits for products and equipment was due to the Company expanding its product line in large quantity container (“Tote”) selling at lower margins as a promotion to clients during the period.

Operating Expenses

Total operating expenses were ~~$417,329,~~$1,027,002, for the ~~three~~six months ended ~~March 31,~~June 30, 2021, and ~~$395,496~~$747,963 for the ~~three~~six months ended ~~March 31,~~June 30, 2020. The ~~decrease of $21,833~~increase in operating expenses is attributed to ~~decreases in expenses~~increases legal, accounting and other third party consultant costs associated with ~~general and administrative legal expenses, offset by~~the closing of the Naturaleaf asset acquisition. The Company has seen additional increases in ~~stock compensation expense~~sales and marketing expenses ~~incurred in connection with~~and web site design during the ~~proposed acquisition of Naturaleaf.~~period.

Other Income (Expense)

Other income (expense) for the ~~three~~six months ended ~~March 31,~~June 30, 2021 was ~~$111,263~~$93,532 as ~~compares~~compared with ~~$5,934~~$16,522 for the ~~three~~six months ended ~~March 31,~~June 30, 2020. The increase is a direct result of the forgiveness of the Company’s then outstanding PPP loan by the Small Business ~~Administration.~~Administration offset by increases in interest expenses resulting from the $1,100,000 promissory note issued in connection with the asset acquisition from Naturaleaf.

Net Loss

Net loss for the ~~three~~six months ended ~~March 31,~~June 30, 2021 was ($~~121,895)~~490,549) as compared to a net loss of ($~~177,547)~~279,310) for the ~~three~~six months ended ~~March 31,~~June 30, 2020.

LIQUIDITY AND CAPITAL RESOURCES

As of ~~March 31,~~June 30, 2021, our primary internal sources of liquidity were our working capital, which included cash and cash equivalents of ~~$2,439,850~~$1,131,833 and accounts receivable of ~~$27,268.~~$23,331. We have seen an increase is liquidity as a result of the asset acquisition of Naturaleaf due to the immediacy the receipt of funds as a result of retail revenue. Additionally, considering that our fixed overhead costs are low, we have the ability to issue stock to compensate employees and management. In prospective, due to the delay in additional states enacting legalization for cannabis products management has initiated raising additional capital as needed to offset general and administrative expenses for at least the next 12 months. Management believes this strategy will adequately provide the necessary liquidity and capital resources to fund our operational and general and administrative expenses for at least the next 12 months.

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the Company issued ~~5,550,000~~6,050,000 registered shares of common stock in exchange for net proceeds of ~~$998,292~~$1,083,542 pursuant to the Common Stock Purchase Agreement entered into on October 11, 2019 with White Lion Capital LLC. The Company has registered 34,000,000 million shares of its common stock to sell to White Lion Capital, LLC on as needed basis for funds to support operational activities.

Operating Activities

Net cash used by operating activities for the ~~three~~six months ended ~~March 31,~~June 30, 2021 was a use of ($~~276,672)~~340,990), compared to net cash used by operating activities of ($~~86,049)~~119,471), for the ~~three~~six months ended ~~March 31,~~June 30, 2020. Increases in cash used were a result of the increases in inventory, prepaid expenses, and prepaid acquisition costs offset by decreases in advances from clients.

Investing Activities

For the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020, investing activities were a use of cash of ($~~4,902)~~1,464,036) and ($~~2,269)~~231) respectively.

The increases were result of the cash payment in the acquisition of the assets of Naturaleaf of $1,100,000, expenditures of equipment and leasehold improvements for the cultivation and dispensary facilities of $360,015.

Financing Activities

During the ~~three~~six months ended ~~March 31,~~June, 2021 proceeds received from financing activities was ~~$998,292~~$1,213,541 and $0$69,503 for the ~~three~~six months ended ~~March 31,~~June 30, 2020. Funds received during the ~~three~~six months ended ~~March 31,~~June 30, 2021 were from the sale of shares of the Company’s registered common ~~stock.~~stock and a receipt of funds from the Company’s second SBA PPP Loan.

Off Balance Sheet Arrangements

As of ~~March 31,~~June 30, 2021, and December 31, 2020, we did not have any off balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Non-GAAP Financial Measures

We use Adjusted EBITDA, a Non-GAAP metric, to monitor our overall business performance. We define Adjusted EBITDA as net income (loss) before interest expense, net, provision for (benefit from) income taxes, stock-based compensation, and certain nonrecurring expenses, which to date have been limited to costs associated with the Reverse Merger. We believe that such adjustments to arrive at Adjusted EBITDA provides us with a more comparable measure for managing our business. We also believe that it is a useful measure for securities analysts, investors, and other interested parties in the evaluation of our Company.

A reconciliation of net income(loss) to Adjusted EBITDA is provided below:

~~A reconciliation of net income(loss) to Adjusted EBITDA is provided below:~~

	Three Months			Three Months			Six Months			Six Months
	Ended March 31,			Ended March 31,			Ended June 30,			Ended June 30,
	2021			2020			2021			2020

Adjusted EBITDA reconciliation:
Net income (loss)	$	(121,895	)	$	(177,547	)	$	(490,549	)	$	(279,310	)
Bad Debt Expense		—			22,500			—			--
Depreciation		3,248			3,000			8,979			7,095
Interest Expense		—			—			—			—
Stock-based compensation to employees		15,664			4,503			28,690			24,162
Adjusted EBITDA	$	(102,093	)	$	(147,544	)	$	(452,880	)	$	(248,053	)

ITEM 3. QUANTITATIVE & QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting Company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer/Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

We carried out an evaluation under the supervision and with the participation of management, including our Chief Executive Officer/Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of ~~March 31,~~June 30, 2021, the end of the period covered by this Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses discussed below.

Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and principal financial officer and effected by the Board, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

·● pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets,

·● provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures of are being made only in accordance with authorizations of our management and directors; and

·● provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Because of our inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management identified the following material weaknesses:

·● we do not have an Audit Committee – While not being legally obligated to have an Audit Committee, it is the management’s view that such a committee, including a financial expert board member, is an utmost important entity level control of the Company’s financial statements. Currently the Board of Directors acts in the capacity of the Audit Committee and does not include a member that is considered to be independent of management to provide the necessary oversight over management’s activities.

·●

we have not performed a risk assessment and mapped our processes to control objectives.

·●

we have not implemented comprehensive entity-level internal controls.

·●

we have not implemented adequate system and manual controls; and

·●

we do not have sufficient segregation of duties.

Our management assessed the effectiveness of internal control over financial reporting as of ~~March 31,~~June 30, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organization of the Treadway Commission (“COSO”) in Internal Control – Integrated Framework (2013). Based on management’s assessment, management concluded that the above material weaknesses have not been remediated and, accordingly, our internal control over financial reporting is not effective as of ~~March 31,~~June 30, 2021.

Remediation of Material Weaknesses

We have designed and plan to implement, or in some cases have already implemented, the specific remediation initiatives described below:

·● We intend to allocate resources to perform a risk assessment and map processes to control objectives and, where necessary, implement and document internal controls in accordance with COSO.

·● Our entity-level controls are, generally, informal and we intend to evaluate current processes, supplement where necessary, and document requirements.

·● While we have implemented procedures to identify, evaluate and record significant transactions, we need to formally document these procedures and evidence the performance of the related controls.

·● We plan to evaluate system and manual controls, identify specific weaknesses, and implement a comprehensive system of internal controls.

PART II—OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

On November 15, 2019, Erin Turoff filed suit against the Company and Mr. Terry Buffalo, our principal executive officer and director, and Mr. Ellis Smith our chief development officer and director, in Denver County District ~~Court.~~Court, case number 19-cv34380. The complaint seeks a declaratory judgement and damages relating to Ms. Turoff’s allegations that while working for the Company, she was misclassified as an independent contractor when she was allegedly an employee of the Company. Ms. Turoff alleges she is owed unpaid overtime, liquidated damages, wages, and other compensatory damages for her misclassification and alleged wrongful terminations. Ms. Turoff’s suit against Mr. Buffalo and Mr. Smith alleges that each are the alter ego of the Company and are therefore jointly and severally liable. ~~The~~All parties have appeared in the case and the case is currently in ~~litigation.~~the discovery. At this time, there is no reasonable basis from which a determination or estimate may be made concerning any contingent liability related to this lawsuit.

ITEM 1A.

RISK FACTORS

We are a smaller reporting Company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~The~~On April 23, 2021, the Company ~~did not issue and~~issued 3,000,000 shares of its ~~unregistered securities during~~restricted common stock as part of the ~~three months ended March 31, 2021.~~acquisition of the assets of Medihemp, LLC, and its wholly owned subsidiary SLAM Enterprises, LLC, and Medical Cannabis Caregivers, Inc. (“Naturaleaf”). The shares were issued to its common owner.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

No senior securities were issued and outstanding during the ~~three~~six months ended ~~March 31,~~June 30, 2021 ~~or 2019.~~and 2020.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

This list is intended to constitute the exhibit index.


31.1	Certification of Principal Executive & Financial Officer as required by Rule 13a-14 or 15d-14 of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Principal Executive & Financial Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes0Oxley Act of 2002.
101.INS	XBRL Instance Document*
101.SCH	XBRL Taxonomy Extension Schema Document*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB	XBRL Taxonomy Extension Label Linkbase Document*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document*

*Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMERICAN CANNABIS COMPANY, INC.

Date: ~~May 10,~~August 13, 2021

~~By:~~ ~~/s/ Terrry Buffalo~~

By:

/s/ Terrry Buffalo

Terry Buffalo,

Chief Executive Officer & Chief Financial Officer

Delaware		90-1116625
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)
2590 Walnut #6
Denver, Colorado		80205
(Address of principal executive offices)		(Zip Code)
~~(303)~~ (303) 974-4770 (Registrant's telephone number, including area code)

		Page
PART I. FINANCIAL INFORMATION

Item 1.	FINANCIAL STATEMENTS:

	CONDENSED CONSOLIDATED BALANCE SHEETS AS OF ~~MARCH 31,~~JUNE 30, 2021 (UNAUDITED) AND DECEMBER 31, 2020	3

	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED ~~MARCH 31,~~JUNE 30, 2021 AND 2020 (UNAUDITED).	4

	CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY FOR THE ~~THREE~~SIX MONTHS ENDED ~~MARCH 31,~~JUNE 30, 2021 AND 2020 (UNAUDITED)	6

	CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 (UNAUDITED).	5

	~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020 (UNAUDITED).~~	6

	NOTES TO THE UNAUDITED CONDENSEND CONSOLIDATED FINANCIAL STATEMENTS.	7

Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	19

~~Item 3.~~	~~QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~	22

~~Item 4.~~	~~CONTROLS AND PROCEDURES~~	22

~~PART II. OTHER INFORMATION~~

~~Item 1.~~	~~LEGAL PROCEEDINGS~~	24

Item ~~1A.~~3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK ~~FACTORS~~	2428

Item 4.	CONTROLS AND PROCEDURES	28

PART II. OTHER INFORMATION

Item 1.	LEGAL PROCEEDINGS	30

Item 1A.	RISK FACTORS	30

Item 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	2430

Item 3.	DEFAULTS UPON SENIOR SECURITIES	2430

Item 4.	MINE SAFETY DISCLOSURES	2430

Item 5.	OTHER INFORMATION	2430

Item 6.	EXHIBITS	2531

SIGNATURES		2632


	March 31,			December 31,			June 30,			December 31,
	2020			2020			2021			2020
ASSETS
Current Assets
Cash and Equivalents	$	2,439,850		$	1,723,132		$	1,131,833		$	1,723,132
Accounts Receivable, Net		27,268			24,955			23,331			24,955
Deposits		2,895			2,895			2,895			2,895
Inventory		121,454			62,402			331,494			62,402
Prepaid Expenses and Other Current Assets		51,195			50,302			24,072			50,302
Total Current Assets		2,642,662			1,863,686			1,513,625			1,863,686

Property and Equipment - Net		22,983			24,655			468,216			24,655

Other Assets
Prepaid Acquisition Costs		20,000			—
Intangible Assets		3,326			—
Intangible Assets, net								1,115,182			-
Goodwill								1,530,316			-
Right of Use Assets - Operating Leases, net								163,416			-
Long Term Deposits								6,001			-
Total Other Assets		23,326			—			2,814,915			-
TOTAL ASSETS	$	2,688,971		$	1,888,341		$	4,796,756		$	1,888,341

LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
Accounts Payable	$	59,965		$	13,153		$	264,468		$	13,153
Advances from Clients		63,224			88,843			63,447			88,843
Accrued and Other Current Liabilities		46,533			49,244			136,368			49,244
Stock payable		15,664			—			28,690			-
Loan Payable		—			109,914
Right of Use Liabilities, current								147,131			-
Note payables, current								1,230,186			109,914
Total Current Liabilities		185,386			261,154			1,870,290			261,154

Long Term Liabilities
Right of Use Liabilities								16,286			-
Total Long Term Liabilities								16,286			-
TOTAL LIABILITIES								1,886,576			261,154
Shareholders' Equity
Preferred Stock, $0.01 par value, 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2021 and December 31, 2020		—			—
Common stock, $0.00001 par value; 500,000,000 shares authorized; 76,377,938 and 70,727,938 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		764			707
Preferred Stock, $0.01 par value, 5,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2021 and December 31, 2020								-			-
Common stock, $0.00001 par value; 500,000,000 shares authorized; 79,902,938 and 70,727,938 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively								798			707
Additional paid-in capital		10,632,984			9,634,748			11,408,199			9,634,748
Accumulated deficit		(8,130,163	)		(8,008,268	)		(8,498,817	)		(8,008,268	)
Total Shareholders' Equity		2,503,585			1,627,187			2,910,180			1,627,187

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	2,688,971		$	1,888,341		$	4,796,756		$	1,888,341


	For The Three Months Ended						For the Six Months Ended
	June 30,			June 30,			June 30,			June 30,
	2021			2020			2021			2020
Revenues
Consulting Services	$	39,501		$	131,238		$	201,393		$	355,613
Product & Equipment		273,401			418,675			437,489			634,682
Cannabis Products		307,077			-			307,077			-
Total Revenues		619,979			549,913			945,958			990,295

Cost of Revenues
Cost of Consulting Services		6,006			22,429			26,706			114,555
Cost of Products and Equipment		209,148			287,368			330,257			423,609
Cost of Cannabis Products		146,074			-			146,074			-
Total Cost of Revenues		361,228			309,797			503,037			538,164
Gross Profit		258,751			240,116			442,921			452,131

Operating Expenses
General and Administrative		535,641			240,187			870,569			560,773
Selling and Marketing		61,006			92,621			127,743			163,028
Stock Based Compensation Expense		13,027			19,659			28,690			24,162
Total Operating Expenses		609,674			352,467			1,027,002			747,963
Loss from Operations		(350,923	)		(112,351	)		(584,081	)		(295,832	)

Other Income (Expense)
Interest (expense)		(18,629	)		-			(18,810	)		-
Debt Forgiveness		-			-			110,543			-
Other income		900			10,588			1,799			16,522
Total Other (Expense) Income		(17,729	)		10,588			93,532			16,522
Net Loss		(368,654	)		(101,763	)		(490,549	)		(279,310	)
Income Tax Expense		-			-			-			-
NET LOSS	$	(368,652	)	$	(101,763	)	$	(490,549	)	$	(279,310	)
Basic net loss per common share	$	(0	)	$	(0	)	$	(0	)	$	(0.01	)
Basic weighted average common shares outstanding		76,256,839			54,206,866			76,329,457			53,460,270

	For the Three Months Ended
	March 31,			March 31,
	2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$	(121,895	)	$	(177,547	)
Adjustments to reconcile net loss to net cash used in operating activities:
Allowance for Bad Debt Expenses		—			22,500
Depreciation		3,248			3,000
Stock-based compensation to employees		15,664			4,503
Debt Forgiveness		(110,543	)		—
Changes in operating assets and liabilities:
Accounts receivable		(2,313	)		(42,524	)
Deposits		—			(2,895	)
Inventory		(59,052	)		(27,720	)
Prepaid expenses and other current assets		(893	)		(4,791	)
Prepaid Acquisition Costs		(20,000	)		—
Right to Use Lease Asset		—			12,662
Accounts Payable		62,196			50,925
Advances from Clients		(25,619	)		44,740
Accrued and other current liabilities		(17,465	)		43,985
Operating Lease Liability		—			(12,887	)
Net Cash used in Operating Activities	$	(276,672	)	$	(86,049	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,576	)		(2,269	)
Intangible assets		(3,326	)		—
Net Cash Provided by (Used in) Investing Activities	$	(4,902	)	$	(2,269	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock		998,292			—
Net Cash Provided by Financing Activities	$	998,292		$	—

NET INCREASE (DECREASE) IN CASH		716,718			(88,318	)

CASH AT BEGINNING OF PERIOD		1,723,132			945,181

CASH AT END OF PERIOD	$	2,439,850		$	856,863

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	—		$	—
Cash paid for interest	$	—		$	—

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐


					Additional					Total
	Common Stock				Paid-In		Accumulated			Shareholders'
	Shares		Amount		Capital		Deficit			Equity

Balance, December 31, 2019		52,978,605	$	529	$	8,354,920	$	(7,475,855	)	$	879,594
Stock-based compensation to employees		478,261		5		43,504		—			43,509
Net Loss		—		—		—		(177,547	)		(177,547	)
Balance, March 31, 2020		53,456,866	$	534	$	8,398,424	$	(7,653,402	)	$	745,556

Balance, December 31, 2020		70,727,938	$	707	$	9,634,748	$	(8,008,268	)	$	1,627,187
Stock issued for cashless exercise		100,000		1		—		—			1
Shares issued for cash		5,550,000		56		998,236		—			998,292
Net Loss		—		—		—		(121,895	)		(121,895	)
Balance, March 31, 2021		76,377,938	$	764	$	10,632,984	$	(8,130,163	)	$	2,503,585